Hawaii 2022 Regular Session

Hawaii House Bill HB17 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	HOUSE OF REPRESENTATIVES H.B. NO. 17 THIRTY-FIRST LEGISLATURE, 2021 STATE OF HAWAII A BILL FOR AN ACT RELATING TO PRESCRIPTION DRUGS. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	HOUSE OF REPRESENTATIVES H.B. NO. 17
4	4	THIRTY-FIRST LEGISLATURE, 2021
5	5	STATE OF HAWAII
6	6
7	7	HOUSE OF REPRESENTATIVES
8	8
9	9	H.B. NO.
10	10
11	11	17
12	12
13	13	THIRTY-FIRST LEGISLATURE, 2021
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	RELATING TO PRESCRIPTION DRUGS.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. Chapter 431R, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows: "§431R- Mandatory notification of prescription drug price increases. (a) A manufacturer of a prescription drug having a wholesale acquisition cost of more than $40 for a course of therapy shall notify each prescription drug benefit plan and pharmacy benefit manager of any planned price increase if that increase will result in a sixteen per cent or more increase in the wholesale acquisition cost of the prescription drug over any two-year period. (b) The notice required by subsection (a) shall: (1) Be provided in writing at least sixty days prior to the planned effective date of the price increase; and (2) Include: (A) The date the price increase shall take effect; (B) The current wholesale acquisition cost of the prescription drug; (C) The dollar amount of the future price increase in the wholesale acquisition cost of the prescription drug; and (D) A statement regarding whether a change or improvement in the drug necessitates the price increase, and if so, a description of the change or improvement. (c) The insurance commissioner shall post on the website of the department of commerce and consumer affairs the names and addresses of the prescription drug benefit plans and pharmacy benefit managers required to receive notice pursuant to this section. (d) A manufacturer of a prescription drug shall identify annually up to ten prescription drugs on which the State spends significant health care moneys and for which the wholesale acquisition cost increased by a total of fifty per cent or more during the prior two calendar years or by twenty per cent or more during the prior calendar year. The drugs identified shall represent different drug classes and shall include generic drugs. (e) For each prescription drug identified pursuant to subsection (d), the insurance commissioner shall require the drug manufacturer to report the following information: (1) A schedule of the drug's wholesale acquisition cost increases over the previous five calendar years; (2) A written narrative description, suitable for public release, of the factors that have contributed to the drug's recent cost increase; (3) The date and price of acquisition of the identified drug if it was not developed by the manufacturer, and the drug's wholesale acquisition cost at the time of acquisition, if known; and (4) The manufacturer's aggregate, company-level research and development and other relevant capital expenditures, such as facility construction, for the most recent year for which final audited data are available." SECTION 2. Section 431R-1, Hawaii Revised Statutes, is amended by adding a new definition to be appropriately inserted and to read as follows: ""Course of therapy" means: (1) The recommended daily dosage units of a prescription drug for thirty days, pursuant to its prescribing label as approved by the United States Food and Drug Administration; or (2) The recommended daily dosage units of a prescription drug pursuant to its prescribing label for a normal course of treatment that is less than thirty days, as approved by the United States Food and Drug Administration." SECTION 3. Section 431R-4, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows: "(a) No later than March 31 of each calendar year, each prescription drug benefit plan, health benefits plan under chapter 87A, and pharmacy benefit manager shall file with the insurance commissioner, in [such] a form and detail as the insurance commissioner shall prescribe, a report for the preceding calendar year stating that the pharmacy benefit manager or prescription drug benefit plan is in compliance with this chapter. The report shall fully disclose the amount, terms, and conditions relating to copayments, reimbursement options, and other payments associated with a prescription drug benefit plan. Each report shall disclose an address that shall be posted on a public website for purposes of receiving notifications pursuant to section 431R- ." SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored. SECTION 5. This Act shall take effect upon its approval. INTRODUCED BY: _____________________________
48	48
49	49	SECTION 1. Chapter 431R, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:
50	50
51	51	"§431R- Mandatory notification of prescription drug price increases. (a) A manufacturer of a prescription drug having a wholesale acquisition cost of more than $40 for a course of therapy shall notify each prescription drug benefit plan and pharmacy benefit manager of any planned price increase if that increase will result in a sixteen per cent or more increase in the wholesale acquisition cost of the prescription drug over any two-year period.
52	52
53	53	(b) The notice required by subsection (a) shall:
54	54
55	55	(1) Be provided in writing at least sixty days prior to the planned effective date of the price increase; and
56	56
57	57	(2) Include:
58	58
59	59	(A) The date the price increase shall take effect;
60	60
61	61	(B) The current wholesale acquisition cost of the prescription drug;
62	62
63	63	(C) The dollar amount of the future price increase in the wholesale acquisition cost of the prescription drug; and
64	64
65	65	(D) A statement regarding whether a change or improvement in the drug necessitates the price increase, and if so, a description of the change or improvement.
66	66
67	67	(c) The insurance commissioner shall post on the website of the department of commerce and consumer affairs the names and addresses of the prescription drug benefit plans and pharmacy benefit managers required to receive notice pursuant to this section.
68	68
69	69	(d) A manufacturer of a prescription drug shall identify annually up to ten prescription drugs on which the State spends significant health care moneys and for which the wholesale acquisition cost increased by a total of fifty per cent or more during the prior two calendar years or by twenty per cent or more during the prior calendar year. The drugs identified shall represent different drug classes and shall include generic drugs.
70	70
71	71	(e) For each prescription drug identified pursuant to subsection (d), the insurance commissioner shall require the drug manufacturer to report the following information:
72	72
73	73	(1) A schedule of the drug's wholesale acquisition cost increases over the previous five calendar years;
74	74
75	75	(2) A written narrative description, suitable for public release, of the factors that have contributed to the drug's recent cost increase;
76	76
77	77	(3) The date and price of acquisition of the identified drug if it was not developed by the manufacturer, and the drug's wholesale acquisition cost at the time of acquisition, if known; and
78	78
79	79	(4) The manufacturer's aggregate, company-level research and development and other relevant capital expenditures, such as facility construction, for the most recent year for which final audited data are available."
80	80
81	81	SECTION 2. Section 431R-1, Hawaii Revised Statutes, is amended by adding a new definition to be appropriately inserted and to read as follows:
82	82
83	83	""Course of therapy" means:
84	84
85	85	(1) The recommended daily dosage units of a prescription drug for thirty days, pursuant to its prescribing label as approved by the United States Food and Drug Administration; or
86	86
87	87	(2) The recommended daily dosage units of a prescription drug pursuant to its prescribing label for a normal course of treatment that is less than thirty days, as approved by the United States Food and Drug Administration."
88	88
89	89	SECTION 3. Section 431R-4, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows:
90	90
91	91	"(a) No later than March 31 of each calendar year, each prescription drug benefit plan, health benefits plan under chapter 87A, and pharmacy benefit manager shall file with the insurance commissioner, in [such] a form and detail as the insurance commissioner shall prescribe, a report for the preceding calendar year stating that the pharmacy benefit manager or prescription drug benefit plan is in compliance with this chapter. The report shall fully disclose the amount, terms, and conditions relating to copayments, reimbursement options, and other payments associated with a prescription drug benefit plan. Each report shall disclose an address that shall be posted on a public website for purposes of receiving notifications pursuant to section 431R- ."
92	92
93	93	SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
94	94
95	95	SECTION 5. This Act shall take effect upon its approval.
96	96
97	97
98	98
99	99	INTRODUCED BY: _____________________________
100	100
101	101	INTRODUCED BY:
102	102
103	103	_____________________________
104	104
105	105
106	106
107	107
108	108
109	109	Report Title: Department of Commerce and Consumer Affairs; Prescription Drugs; Price Increases; Notification; Insurance Commissioner Description: Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two‑year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame. The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
110	110
111	111
112	112
113	113
114	114
115	115	Report Title:
116	116
117	117	Department of Commerce and Consumer Affairs; Prescription Drugs; Price Increases; Notification; Insurance Commissioner
118	118
119	119
120	120
121	121	Description:
122	122
123	123	Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two‑year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame.
124	124
125	125
126	126
127	127
128	128
129	129
130	130
131	131	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.